Chimpanzee Adenovirus Vector Ebola Vaccine
New England Journal of Medicine2014Vol. 376(10), pp. 928–938
Citations Over TimeTop 1% of 2014 papers
Julie E. Ledgerwood, Adam DeZure, Daphne A. Stanley, Emily E. Coates, Laura Novik, Mary E. Enama, Nina M. Berkowitz, Zonghui Hu, Gyan Joshi, Aurélie Ploquin, Sandra Sitar, Ingelise J. Gordon, Sarah A. Plummer, LaSonji A. Holman, Cynthia S. Hendel, Galina V. Yamshchikov, François Roman, Alfredo Nicosia, Stefano Colloca, Riccardo Cortese, Robert T. Bailer, Richard Schwartz, Mario Roederer, John R. Mascola, Richard A. Koup, Nancy J. Sullivan, Barney S. Graham
Abstract
Reactogenicity and immune responses to cAd3-EBO vaccine were dose-dependent. At the 2×1011 particle-unit dose, glycoprotein Zaire-specific antibody responses were in the range reported to be associated with vaccine-induced protective immunity in challenge studies involving nonhuman primates, and responses were sustained to week 48. Phase 2 studies and efficacy trials assessing cAd3-EBO are in progress. (Funded by the Intramural Research Program of the National Institutes of Health; VRC 207 ClinicalTrials.gov number, NCT02231866 .).
Related Papers
- → Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!)(2016)1,068 cited
- → Recombinant Vesicular Stomatitis Virus–Based Vaccines Against Ebola and Marburg Virus Infections(2011)224 cited
- → Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV(2019)122 cited
- → Experts hopeful about Ebola control in Uganda(2022)4 cited
- [Recent Advances in Vaccines and Drugs Against the Ebola Virus].(2015)